Season 11: episode 3
This week, Isabel sits down with Hanna Svanbäck, Executive Director for Neuroscience, Eli Lilly, for an insightful discussion on the evolving landscape of Alzheimer’s research. Together, they explore the latest breakthroughs, the challenges ahead and the strategies shaping the future of treatment and prevention.
In the episode, Hanna reflects on her path into neuroscience and shares how she inspires resilience and purpose within her teams during times of uncertainty. She also highlights the most exciting developments in early detection and biomarkers, and offers a forward-looking perspective on how clinical trials can become more impactful and patient-centered in the years to come.
Quickfire questions
Deep dives
Speaker bio
Hanna Svanbäck is the Executive Director for Neuroscience, Eli Lilly, overseeing operations in the UK, Ireland and the Nordic countries. Hanna has over 15 years of experience at Lilly and is proud to lead the Neurosciences function given Lilly’s long-standing commitment to advancing scientific innovation in this field. Hanna’s passion for science and her dedication to utilising innovative approaches to enhance patient care are underpinned by her academic studies in Engineering Genomics and Biotechnology from the University of Umeå, Sweden and University of Manchester.
